Scientists from the National Institute of Allergy and Infectious Diseases (NIAID) announced on Monday improvements to an experimental vaccine designed to spur production of antibodies against the AMA1 malaria parasite protein.
The new candidate delivers AMA1 protein together with part of another parasite protein, RON2.
The AMA1-RON2 complex is used to attach malaria parasites to red blood cells. The vaccine, when injected into mice, prompted an antibody response that protected the mice from lethal forms of the disease.
Additionally, antibodies produced in response to the AMA1-RON2 vaccine offered protection when administered to non-vaccinated mice as well.
The research suggests that the method could be used in testing on human malaria vaccines.
Common Management Taxonomy: